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ABSTRACT
The aim of this study is to investigate the 
prevalence and carriage of Extended Spec-
trum Beta-Lactamase (ESBL) and AmpC-
producing strains of E. coli and Klebsi-
ella spp in hospitalized dogs treated with 
antimicrobials. Tissue and fecal samples 
from 66 dogs were analyzed for presence 
of AmpC or ESBL producing bacteria. 
The dogs had to have been admitted to the 
surgical ward for at least 24 hours and have 
received antimicrobial treatment. Samples 
were plated onto bovine blood agar and 
after incubation for 24 + 24 h, five colonies 
morphologically consistent with E.coli and 
Klebsiella spp, were selected and recultured 
onto media containing antimicrobials. Dogs 
carrying ESBL/AmpC- producing bacteria 
were retested for rectal colonisation at 3-6 
months intervals for up to 16 months. Five 
(7.6%) dogs carried bacterial strains posi-
tive for ESBL/AmpC- producing- genes 
in feces. All tissue samples were negative. 
One dog, previously positive for blaCMY-2, 
carried ESBL genotype blaTEM-52, in the 
second sample. Four dogs remained posi-
tive throughout the testing. None of the dogs 
had signs of infection or symptoms associ-
ated with the carriage of ESBL or plasmid 
mediated-AmpC- producing bacteria. Seven 
unique MLVA-types were identified. The 
results from this study show fecal car-
riage for as long as 16 months of ESBL/
AmpC- producing E.coli in dogs treated 
with antimicrobials. Although clonal spread 
could not be verified in this study, the risk 
of dissemination of multiresistant bacteria in 
animal hospitals and in the community must 
be considered. 
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INTRODUCTION
Antimicrobial resistance is a large and 
increasing problem in both human (Coque 
et al 2008) and veterinary medicine (Wieler 
et al 2011). The use and misuse of antibiot-
ics has played a role in the emergence and 
spread of resistant bacteria in animal and 
human hospitals and in the community 
(Rantala et al 2004, Dietrix et al 2004). The 
Infectious Diseases Society of America 
has listed Escherichia coli and Klebsiella 
spp as two out of six pathogens for which 
new drugs are urgently needed in order to 
combat resistance development (Talbot et 
al 2006). Resistance to extended spectrum 
cephalosporins is particularly worrying, as 
it is considered by the World Health Orga-
nization (WHO) to be a critically important 
antibiotic for human medicine (WHO 2007). 
The production of extended-spectrum beta-
lactamases (ESBL) and AmpC enzymes 
results in resistance to the majority of the 
commonly used beta-lactam antimicrobials, 
including third generation cephalosporins 
(Pitout 2010). ESBL is frequently plasmid-
mediated and AmpC beta lactamase activity 
is chromosomal (cAmpC)- or plasmid-me-
diated (pAmpC) (Peter-Getzlaff et al 2011). 
The location of genes in plasmids means 
that they can be transferred via horizontal 
gene transfer between bacteria within and 
between bacterial species (Brolund et al 
2013). Another clinical challenge is that 
ESBL/AmpC- producing isolates are com-
monly multi-drug resistant resulting in that 
the numbers of treatment options often are 
few.
European studies show noticeable 
high numbers of ESBL/AmpC- producing 
E.coli in clinical samples from horses and 
dogs primarily with diarrhea (Dietrix et al 
2012, Swedres-SVARM 2012, Hordijk et al 
2013), as well as in samples from healthy 
dogs (Hordijk et al 2013). In Scandinavia 
there are only a limited number of studies 
describing the prevalence of ESBL/AmpC 
in dogs. The Swedish Veterinary Institute 
(SVA) screened 84 healthy dogs for ESBL/
AmpC- producing E.coli in feces in 2012, 
and one isolate of pAmpC was detected 
(1%) (Swedres-SVARM 2012). Of the 15 re-
sistant E.coli isolates from urogenital tracts 
or wounds referred to SVA during 2011, 
12 isolates were ESBL/pAmpC- producing 
(Swedres-SVARM 2012). 
The main purpose of this study was to 
investigate the presence of ESBL/AmpC-
producing strains of E. coli and Klebsiella 
spp in surgical sites and feces in hospitalized 
surgically treated dogs, treated with antimi-
crobials and the fecal carriage over time. 
MATERIALS AND METHODS
Animal welfare
Ethical approval for this study was granted 
by the Uppsala Ethical Committee, Uppsala, 
Sweden. The board of agriculture approved 
the use of client-owned dogs. All dog own-
ers had to provide written consent before 
their dogs were enrolled in the study.
Sampling of patients
Two Swedish animal hospitals par-
ticipated in the study: A University Animal 
Hospital and a Referral Animal Hospital. To 
be enrolled in the study, dogs were required 
to meet the inclusion criteria; admitted to 
the animal hospital for at least 24 hours and 
have received antimicrobial treatment for 
at least 24 hours within the last month. The 
criteria were based on the identified risk 
factors for ESBL compiled by the Swed-
ish National Board of Health (STRAMA) 
where factors such as hospitalization and 
use of antibiotics, in particular cephalospo-
rins and fluoroquinolones, are considered to 
contribute to the development of resistance 
(STRAMA 2007). 
Samples were taken from wound or dis-
eased tissue and from feces (carrier sample) 
between January 2012 and June 2014 with 
a Copan swab in Aimes medium (Copan, 
Italy). Samples from the University Animal 
Hospital were cultured within 24 hours and 
samples from the Referral Animal Hospital, 
within 36 hours. 
From dogs shown to carry ESBL or 
AmpC producing- E. coli or Klebsiella spp, 
three new samples were collected from feces 
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with 3-6 months intervals, to evaluate if the 
dog was still a carrier of the bacteria. When 
it was impossible for the owners to bring in 
their animals to the clinic for follow-up test-
ing, they were given the option of swabbing 
the feces of their animals themselves and 
then sending it in immediately for culturing.  
Bacterial isolation and phenotypic 
identification
Tissue samples were plated onto bovine 
blood agar (National Veterinary Institute, 
Uppsala, Sweden) and MacConkey agar 
supplemented with cefotaxime 1mg/L (Na-
tional Veterinary Institute, Uppsala, Sweden) 
and incubated at 37° for 24 hours and then 
another 24 hours. Fecal samples were plated 
onto MacConkey agar supplemented with 
cefotaxime 1mg/L (National Veterinary 
Institute, Uppsala, Sweden) and incubated at 
37° for 24 hours and then a further 24 hours. 
After plating, fecal swabs were placed in 
MacConkey broth supplemented with cefo-
taxime 1mg/L (National Veterinary Institute, 
Uppsala, Sweden) and incubated for 24 
hours at 37°C. Twenty μL were then spread 
onto MacConkey agar supplemented with 
cefoxitime 1mg/L. Plates were incubated 
aerobically for 24+24 hours. If the direct 
plating culture were positive, the cultures 
from pre-enrichments were disregarded. 
Five colonies from primary culture or en-
richment culture, morphologically consistent 
with E.coli and Klebsiella spp, were selected 
and recultured onto bovine blood agar plates 
(SVA, Uppsala, Sweden) and purple agar 
with lactose (SVA, Uppsala, Sweden) and 
incubated for 24 hours. Oxidase-negative 
(Becton, Dickinson and Company (BD), 
USA) strains were confirmed as E.coli or 
Klebsiella spp with API20E (Bio Merieux, 
France).
Antimicrobial susceptibility test
Antimicrobial susceptibility testing was 
performed using broth micro dilution (Vet-
MICGN-moE-395103, National Veterinary 
Institute, Uppsala, Sweden), and control 
strain CCUG 17620 (ATCC 25922).
On strains resistant to ampicillin (break-
point >16mg/L) and cefotaxime (break-
point >0,25mg/L), ESBL-detection testing 
according to CLSI guidelines (Clinical and 
Laboratory Standards Institute, 2010 CLSI 
document M100-S16 (ISBN 1-56238-588-
7)) and AmpC detection testing according 
to RAF (http://www.srga.org/rafmetod/beta-
mas.htm) were performed. Negative control 
strain CCUG 17620 (ATCC 25922) and 
positive control strain CCUG 45421 (ATCC 
700603) were used.  
Genotypic characterization
E. coli isolates confirmed to be producing 
pAmpC or ESBL were screened for the 
presence of gene groups blaCTX-M, blaTEM, 
blaSHV, blaOXA-1, and genes encoding pAmpC 
(Fang et al 2008, Perez-Perez et al 2002 and 
Woodford et al 2006). Isolates PCR-positive 
for any of the genes were subjected to se-
quencing as previously described (Egervärn 
et al 2014). To establish a possible clonal 
relationship, ESBL and pAmpC- producing 
E. coli isolates were subjected to Multiple-
Locus Variable number tandem repeat 
Analysis (MLVA) (Lobersli et al 2012).
Statistical analysis
All results are presented as mean±standard 
deviation. A one-way ANOVA was used 
for analyzing the difference between the 
positive and negative groups, using JMP 10 
(SAS Institute, Cary, NC, USA). A P-value 
of 0.05 was considered significant.
RESULTS 
Sixty-six dogs of various breeds were in-
cluded in the study. All the dogs tested were 
admitted to the surgical wards for at least 
24 hours because of a variety of surgical 
diseases. The median age of the dogs was 7 
(1-13) years old. Of the included dogs, five 
(henceforth referred to as dogs A-E) were 
positive for plasmid or chromosomal AmpC- 
producing E. coli (7.6 %) showing AmpC 
phenotype, in the first fecal sample (Table 
1). 6 % of the included dogs were positive 
for plasmid AmpC. No ESBL/AmpC- pro-
ducing E.coli or Klebsiella spp. could be 
identified in samples from surgical sites, a 
variety of other bacteria were found in the 
surgical sites and were probably the source 
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of infection. None of the dogs showed signs 
of infection or symptoms related to their 
carriage of ESBL/pAmpC- producing E. 
coli such as wound dehiscence or prolonged 
healing time. The E. coli isolates collected 
from dogs A-C and E were described to 
carry the blaCMY-2, due to the plasmid 
AmpC. The isolate from dog D was negative 
for all genes tested, indicating a chromo-
somal AmpC. No ESBL/AmpC- producing 
Klebsiella bacteria were found. The bacte-
rial strains from dog A-E showed resistance 
to ampicillin and to the third-generation 
cephalosporines cefotaxime and ceftazidime 
(table 2). The first isolate from dog A was 
also resistant to sulfamethoxazole and trim-
ethoprim and the second isolate from dog E 
was additionally resistant to ciprofloxacin 
and nalidixic acid (table 2). 
 At retesting after 3-5 months, E. coli 
isolates carrying blaCMY-2 were found in fecal 
samples in dogs A, C, and E, while dog B 
was negative. Further testing of dog A after 
five months was not possible due to eutha-
nasia because of degenerative joint disease. 
The second retesting took place 11-16 
months after initial testing and at this time 
dogs C and D remained positive for phe-
notypically AmpC- producing E. coli, but 
no plasmid-associated genes were detected. 
The primary sample on dog E revealed two 
phenotypically different E. coli colonies, 
lactose fermenting and non-fermenting, and 
both isolates carried blaCMY-2. On the first 
retesting of dog E three months after initial 
testing, E. coli carrying blaCMY-2 could no 
longer be detected. However, dog E was on 
this occasion positive for ESBL- produc-
ing E.coli carrying blaTEM-52 . On the second 
retesting of dog E 16 months after primary 
sampling it was positive for E. coli carrying 
blaCMY-2 but isolates carrying blaTEM-52 could 
no longer be found.
For the nine E. coli isolates carrying 
blaCMY-2 (table 1), seven unique MLVA types 
differing in two or more alleles were de-
scribed. The isolates sharing identical MLVA 
types were isolated from dog C eleven 
months apart (table 3).
The dogs in the study had all been 
treated with various antibiotics, the most 
common being amoxicillin (Table 1). The 
length of the antibiotic treatment in the 
group where isolates of ESBL, pAmpC or 
cAmpC was found was 8±6.7 days. In the 
group where no ESBL, pAmpC or cAmpC 
was found, the length was 7.5±8.7 days. In 
the ESBL, pAmpC or cAmpC group the 
average time of hospitalization was 3.8±2.2 
days; in the other group it was 2.8±1.5 days. 
There was no significant difference between 
the groups regarding length of treatment 
(P=0.88) or hospitalization (P=0.36). 
DISCUSSION
In Sweden the occurrence of clinical 
isolates of ESBL and pAmpC- producing 
Enterobacteriaceae among dogs appears to 
be uncommon. Only 15 isolates resistant to 
3rd-generation cephalosporins were submit-
ted from dogs to the National Veterinary 
Institute for further analysis during 2012, 
and twelve were found to be producing 
ESBL or pAmpC (Swedres-SVARM 2012). 
Dog diagnosis length of 
hospitalization
antimicrobial length of 
treatment
1:st sample 2:nd sample
3-5 months
3:rd sample
11-16 months
A abscess 3 days enro 2 days blaCMY-2  blaCMY-2  blaTEM-1
B ectopic 
ureters
1 day amox 9 days blaCMY-2 negative negative
C ssi 6 days amox 4 days blaCMY-2 blaTEM-1 blaCMY-2  blaCMY-2  blaTEM-1
D ssi 6 days cepha 19 days Neg Neg Neg
E bite wound 3 days amox 6 days blaCMY-2 blaTEM-52   blaCMY-2  
Table 1. AmpC- genes of positive tested dogs
Antimicrobial: enro = enrofloxacin, amox=amoxicillin, cepha=cephalosporin 1:st generation
Ssi = surgical site infection
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Furthermore, a study during 2012, utilizing 
the same methodology as this study, describ-
ing intestinal carriage in healthy dogs found 
pAmpC- producing E. coli in only 1 % of 
the samples (Swedres-SVARM 2012). This 
differs from the current study were 6 % of 
Swedish dogs hospitalized in surgical wards 
and treated with antimicrobials for surgical 
diseases carried pAmpC- producing E. coli 
isolates. The results might therefore indi-
cate that hospitalization in a surgical ward 
combined with antimicrobial therapy can 
increase the occurance of ESBL/pAmpC- 
producing E. coli in dogs. This assumption 
is also supported by previous studies for 
example one study by Damborg et al (2012) 
that studied the effect of antimicrobial 
prophylactic treatment on the emergence 
and maintenance of ESBL/AmpC-producing 
coliforms in a longitudinal study in horses. 
They described the emergence of ESBL/
AmpC- producing strains from day 1-2 after 
treatment until up to three weeks, when the 
last sample was performed. In addition a 
Korean study by Nam et al 2010 describing 
higher carriage of antibiotic resistant E. coli 
in hospitalized dogs compared to stray dogs. 
Despite the higher carriage in hospitalized 
dogs compared to healthy dogs the situation 
in Sweden is still favorable compared to 
international studies. In a Dutch study, intes-
tinal carriage of pAmpC/ESBL- producing 
E.coli was reported in 45% of healthy dogs 
and in 55% of dogs with diarrhea (Hordijk 
et al 2013). In addition, in another Korean 
study, ESBL and pAmp-C-producing E.coli 
were found in 33,3 and 23,8%, respectively, 
of the isolates from hospitalized dogs (So 
et al 2012). In a Spanish study of healthy 
dogs, 2,65% of the dogs harboured fecal 
E.coli isolates with reduced susceptibility to 
cefotaxime (Costa et al 2008). However, that 
study used only non-selective cultivation; 
hence the real carriage of E.coli isolates with 
reduced susceptibility to cefotaxime was 
probably higher. 
The E. coli carrying blaCMY-2 dominates 
in our study and among clinical submissions 
to the National Veterinary Institute during 
2012 (Swedres-SVARM 2012). Only one of 
our isolates was confirmed to produce ESBL 
carrying blaTEM-52. Interestingly, this isolate 
was identified in a retest of a dog previously 
positive for an isolate with a blaCMY-2. How-
ever, since only a few colonies were chosen 
for analysis, there is the possibility that the 
blaTEM-52 were missed in the first sample and 
vice versa with the blaCMY-2 in the second 
sample. The blaTEM-52  ESBL- gene-type 
has been isolated from clinical samples 
from dogs in a Dutch study (Dietrikx et al 
2012), and in the present study the isolate 
may have been acquired in the hospital. 
The pAmpC-genes are commonly found in 
clinical isolates from dogs around the globe, 
and mostly from urinary samples (Dietrikx 
et al 2012, Hordijk et al 2013, Wagner et 
al 2014, O’Keefe et al 2010). PAmpC can 
pose a further clinical challenge compared to 
ESBL due to the fact that the beta-lactamase 
inhibitors such as clavulanic acid are not 
available as a treatment option. However, 
isolates of pAmpC-type from urinary tract 
infections has been shown to have a reduced 
virulence genotype (Wagner et al, 2014). 
The difference in prevalence and occurrence 
of different genes between different studies 
can have several explanations. These include 
geographic differences, selection of animals, 
methods used for sampling, antibiotic usage 
and bacterial isolation (such as enrichment 
procedures and the media applied). In our 
study, one isolate (dog A, sample 2) came 
out positive for AmpC after enrichment and 
could not be found on direct plating.
In the present study we also showed 
that the dogs can carry E. coli with blaCMY-2, 
for up to at least 16 months after the initial 
sampling. This is to our knowledge, the 
first study to describe prolonged carriage 
of AmpC-producing E.coli in dogs. Indi-
cating that it is important to be aware that 
dogs once diagnosed as carrying ESBL/
AmpC can pose a risk for transmission for 
several months in both the hospital and in 
the community. Maddox et al (2012) found 
that horses stabled together with recently 
hospitalized horses had increased risk for 
acquiring ESBL producing E.coli. Clonal 
spread of ESBL/AmpC producing E.coli in 
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veterinary hospitals has been suggested by 
So et al (2012). In our study we identified 
unique MLVA patterns for isolates from all 
dogs, indicating that the occurrence was not 
due to clonal spread. However, only a small 
number of isolates from every dog were 
analyzed and it is likely that a dog can carry 
several different E. coli encoding pAmpC/
ESBL. We also found two phenotypically 
different E.coli carrying blaCMY-2 in the same 
sample in dog E, and different clones in dog 
C at the first and second testing.  Further-
more, we cannot exclude the possibility 
that spread of one specific plasmid carrying 
blaCMY-2 has occurred. One should also be 
aware of the possibility that such a plasmid 
can transferred in the intestine of the dogs 
even without a selective pressure.  
Antibiotic treatment within the last three 
months before sampling has been identified 
as a risk factor for colonization with ESBL-
producing Enterobactriaceae in healthy 
dogs and cats (Gandolfi-Descristophoris et al 
2010). Furthermore, Damborg et al showed 
that first generation cephalosporins and 
aminopenicillins with clavulanic acid might 
select for E.coli producing pAmpC (2011). 
In the present study dogs were treated with 
antibiotics within a month before sampling 
and the dogs harbouring the E. coli with 
blaCMY-2 had been treated with amoxicillin, 
a first generation cephalosporin, or enro-
floxacin (table 2). However, the treatment 
and length of treatment of the dogs car-
rying E. coli with blaCMY-2 did not signifi-
cantly differ from the negative group. First 
generation cephalosporins are widely used 
in veterinary medicine (Hughes et al 2013), 
but since 2006 there has been a decrease in 
prescription of cephalosporines (-70%) and 
aminopenicillin with clavulanic acid (-52%) 
in Sweden (Swedres-SVARM 2012). This 
decrease in prescription of cephalosporines 
is likely connected to emerging resistance 
problems in farm animals and companion 
animals leading to a larger awareness among 
veterinarians concerning this. It is not 
uncommon that the plasmids carrying the 
ESBL and pAmpC genes often carry genes 
encoding resistance against other antimicro-
bial groups, for example fluoroquinolones 
(Pitout 2010). Fluoroquinolones are fre-
quently used in treating dogs (Guardabassi 
et al 2004), and in our study the ESBL- bla-
TEM-52 isolate (dog E) was fluoroquinolone 
resistant, all of the other AmpC-producing 
isolates were sensitive to fluoroquinolones. 
In 2014 a new law was implemented in 
Sweden which stated that fluoroquinolones 
are only available to veterinarians after an 
antimicrobial susceptibility test have shown 
that it is the only treatment option at hand to 
try and decrease the usage of that antimicro-
bial group. 
The nosocomial spread of highly re-
sistant bacteria emphasizes the importance 
of hygiene routines in veterinary clinics 
(Wieler et al 2011). Besides direct con-
tact, the contamination of the environment 
poses a risk for spread of resistant bacteria 
between dogs and to human contact areas. 
The close contact between pets and humans 
implicates a risk for zoonotic transfer of 
resistance genes, and might constitute a 
public health risk. Dierikx et al (2012) found 
the same ESBL genotypes in isolates from 
dogs and from humans in the Netherlands 
and suggests possible transmission between 
companion animals and humans. 
In conclusion, dissemination of plasmid-
mediated AmpC/ESBL- producing Entero-
bacteriaeae in the hospital environment and 
the community, must be considered as a 
major threat to animal and human health and 
welfare and need to be carefully monitored 
in all surgical wards and intensive care units. 
The potential carriership of several months 
may contribute to community-acquired in-
fections affecting other animals and humans. 
Strict hygiene should be maintained around 
these animals and in particular their feces 
to prevent spread of resistance genes in the 
environment.  
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